Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CATALYST BIOSCIENCES, INC.

(CBIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Catalyst Biosciences to Seek Buyer for its Hemophilia Assets

11/15/2021 | 10:08am EST

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) announced a strategic decision to halt the clinical development of MarzAA, report data to date, and seek a buyer for its hemophilia assets. Catalyst plans to focus its resources on its complement therapeutics and protease medicines platform. The Company also reported its operating and financial results for the third quarter ended September 30, 2021. Dr. Nassim Usman, Ph.D., Chief Executive Officer continued: "We are exploring opportunities to license or sell our MarzAA and DalcA (engineered FIX) portfolios and will donate any standard-of-care to the centers where patients are enrolled. Halting development of MarzAA will allow us to reduce our burn rate by approximately 40% and focus our investment on our highly promising complement therapeutics and protease medicines platform. We want to thank our study subjects, clinical trial investigators and site staff, employees, and investors for their partnership and commitment to the MarzAA programs over the last several years".


ę S&P Capital IQ 2021
All news about CATALYST BIOSCIENCES, INC.
01/25Catalyst Biosciences Secures Rare Pediatric Disease Designation for Immune Defect Drug
MT
01/25Catalyst Biosciences Shares Rise Premarket After Key FDA Designation
DJ
01/25CATALYST BIOSCIENCES : Receives Rare Pediatric Disease Designation for CB 4332 for the Tre..
PU
01/25CATALYST BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/25Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Tr..
AQ
01/12CATALYST BIOSCIENCES : Investor presentation 5.9 MB
PU
01/12CATALYST BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
AQ
2021Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Con..
AQ
2021CATALYST BIOSCIENCES : Investor presentation 4.7 MB
PU
2021Catalyst Biosciences Announces Change in Corporate Strategy
AQ
More news
Analyst Recommendations on CATALYST BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 5,15 M - -
Net income 2021 -89,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,20x
Yield 2021 -
Capitalization 18,4 M 18,4 M -
Capi. / Sales 2021 3,57x
Capi. / Sales 2022 2,45x
Nbr of Employees 56
Free-Float 94,3%
Chart CATALYST BIOSCIENCES, INC.
Duration : Period :
Catalyst Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALYST BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,59 $
Average target price 11,00 $
Spread / Average Target 1 778%
EPS Revisions
Managers and Directors
Nassim Usman President, Chief Executive Officer & Director
Seline E. Miller Chief Financial & Accounting Officer
Augustine J. Lawlor Chairman
Andrew Hetherington Senior Vice President-Technical Operations
Grant Blouse Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CATALYST BIOSCIENCES, INC.-35.93%18
GILEAD SCIENCES, INC.-5.19%86 352
REGENERON PHARMACEUTICALS-4.49%63 067
VERTEX PHARMACEUTICALS3.42%57 743
WUXI APPTEC CO., LTD.-7.49%50 700
BIONTECH SE-39.30%37 796